Capromorelin
Aliases: Entyce · Elura
Last verified: 2026-09-23
The short version
An oral ghrelin agonist — approved in veterinary medicine (Entyce for dog appetite, Elura for cat cachexia); human development (Phase II sarcopenia) stopped.
Identity & type
- Molecular type
- mali molekul
- Origin
- An oral ghrelin agonist — approved in veterinary medicine (Entyce for dog appetite, Elura for cat cachexia); human development (Phase II sarcopenia) stopped.
Mechanism of action
GHS-R1a agonism.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Veterinary: 3 mg/kg orally (dogs).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Veterinary: 3 mg/kg orally (dogs). Veterinary: dog/cat owners report rapid appetite return; humans do not use it.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Veterinary: dog/cat owners report rapid appetite return; humans do not use it.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Human Phase II (sarcopenia): lean-mass gains, inadequate functional benefit.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Veterinary: vomiting, hypersalivation.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials